Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
Journal for ImmunoTherapy of Cancer · 2024-08 · 12 (8) · e008872
DOI: 10.1136/jitc-2024-008872 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 06.08.2024. Verfasst von Michael Schenker und 27 weiteren Autor:innen. Beteiligte Einrichtung: Sf Nectarie Oncology Center and University of Medicine and Pharmacy, Craiova, Romania. Hauptthemen laut MEDLINE: Nivolumab, Ipilimumab, Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bristol Myers Squibb.
Abstract (Originalsprache)
Background
Checkpoint inhibitor therapy has demonstrated overall survival benefit in multiple tumor types. Tumor mutational burden (TMB) is a predictive biomarker for response to immunotherapies. This study evaluated the efficacy of nivolumab+ipilimumab in multiple tumor types based on TMB status evaluated using either tumor tissue (tTMB) or circulating tumor DNA in the blood (bTMB). Patients and methods Patients with metastatic or unresectable solid tumors with high (≥10 mutations per megabase) tTMB (tTMB-H) and/or bTMB (bTMB-H) who were refractory to standard therapies were randomized 2:1 to receive nivolumab+ipilimumab or nivolumab monotherapy in an open-label, phase 2 study (CheckMate 848; NCT03668119 ). tTMB and bTMB were determined by the Foundation Medicine FoundationOne ® CDx test and bTMB Clinical Trial Assay, respectively. The dual primary endpoints were objective response rate (ORR) in patients with tTMB-H and/or bTMB-H tumors treated with nivolumab+ipilimumab.
Results
In total, 201 patients refractory to standard therapies were randomized: 135 had tTMB-H and 125 had bTMB-H; 82 patients had dual tTMB-H/bTMB-H. In patients with tTMB-H, ORR was 38.6% (95% CI 28.4% to 49.6%) with nivolumab+ipilimumab and 29.8% (95% CI 17.3% to 44.9%) with nivolumab monotherapy. In patients with bTMB-H, ORR was 22.5% (95% CI 13.9% to 33.2%) with nivolumab+ipilimumab and 15.6% (95% CI 6.5% to 29.5%) with nivolumab monotherapy. Early and durable responses to treatment with nivolumab+ipilimumab were seen in patients with tTMB-H or bTMB-H. The safety profile of nivolumab+ipilimumab was manageable, with no new safety signals.
Conclusions
Patients with metastatic or unresectable solid tumors with TMB-H, as determined by tissue biopsy or by blood sample when tissue biopsy is unavailable, who have no other treatment options, may benefit from nivolumab+ipilimumab. Trial registration number NCT03668119 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sf Nectarie Oncology Center and University of Medicine and Pharmacy, Craiova, Romania.
- Bradford Hill Clinical Research Center, Santiago, Chile.
- Fundación Richardet Longo, Instituto Oncológico de Córdoba, Córdoba, Argentina.
- Department of Oncology, Oncology Institute Prof Dr Ion Chiricuta, Cluj-Napoca, Romania.
- Iuliu Hațieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.
- Department of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
ORCID-Profile: Paolo A Ascierto, Jonathan Baden, Massimo Di Nicola
Förderung
- Bristol Myers Squibb
Zitieren
APA
Schenker, M., Burotto, M., Richardet, M., Ciuleanu, T. E., Gonçalves, A., Steeghs, N., Schoffski, P., Ascierto, P. A., Maio, M., Lugowska, I., Lupinacci, L., Leary, A., Delord, J. P., Grasselli, J., Tan, D. S. P., Friedmann, J., Vuky, J., Tschaika, M., Konduru, S., …, & Di Nicola, M. (2024). Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden. Journal for ImmunoTherapy of Cancer, 12(8), e008872. https://doi.org/10.1136/jitc-2024-008872
Vancouver
Schenker M, Burotto M, Richardet M, Ciuleanu TE, Gonçalves A, Steeghs N, et al. Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden. Journal for ImmunoTherapy of Cancer. 2024;12(8):e008872. doi:10.1136/jitc-2024-008872
BibTeX
@article{Schenker2024,
author = {Schenker, Michael and Burotto, Mauricio and Richardet, Martin and Ciuleanu, Tudor-Eliade and Gonçalves, Anthony and Steeghs, Neeltje and Schoffski, Patrick and Ascierto, Paolo A and Maio, Michele and Lugowska, Iwona and Lupinacci, Lorena and Leary, Alexandra and Delord, Jean-Pierre and Grasselli, Julieta and Tan, David S P and Friedmann, Jennifer and Vuky, Jacqueline and Tschaika, Marina and Konduru, Somasekhar and Vemula, Sai Vikram and Slepetis, Ruta and Kollia, Georgia and Pacius, Misena and Duong, Quyen and Huang, Ning and Doshi, Parul and Baden, Jonathan and Di Nicola, Massimo},
title = {Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2024},
volume = {12},
number = {8},
pages = {e008872},
doi = {10.1136/jitc-2024-008872}
}
EUVIMED